OncoMatch/Clinical Trials/NCT05780372
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
Is NCT05780372 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Chemotherapy for nasopharyngeal carcinoma.
Treatment: Chemotherapy — This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. The purpose of this study is to evaluate the efficacy of reduced neck prophylactic radiotherapy versus conventional neck prophylactic radiotherapy, and compare the radiotherapy-related adverse events and quality of life in two groups.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage I, II, III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Cannot have received: chemotherapy
Cannot have received: immunotherapy
Lab requirements
Blood counts
white blood cell count ≥ 4×109/l, neutrophile granulocyte count ≥ 1.5×109/l, hemoglobin ≥ 9g/l, platelet count ≥ 100×109/l
Kidney function
blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml/min (cockcroft-gault formula)
Liver function
alanine aminotransferase or aspartate aminotransferase < 2.5×upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify